A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers

Kristen K. Pierce, Stephen S. Whitehead, Beth D. Kirkpatrick, Palmtama L. Grier, Adrienne Jarvis, Heather Kenney, Marya P. Carmolli, Cynthia Reynolds, Cecilia M. Tibery, Janece Lovchik, Anna Janiak, Catherine J. Luke, Anna P. Durbin, Alexander G. Pletnev

Research output: Contribution to journalArticlepeer-review

Abstract

West Nile virus (WNV) is a major cause of mosquito-borne illness in the United States. Human disease ranges from mild febrile illness to severe fatal neurologic infection. Adults aged >60 years are more susceptible to neuroinvasive disease accompanied by a high mortality rate or long-lasting neurologic sequelae. A chimeric live attenuated West Nile virus vaccine, rWN/DEN4Δ30, was shown to be safe and immunogenic in healthy adults aged 18-50 years. This study evaluated rWN/DEN4Δ30 in flavivirus-naive adults aged 50-65 years and found it to be safe and immunogenic. Outbreaks of WNV infection tend to be unpredictable, and a safe and effective vaccine will be an important public health tool.

Original languageEnglish (US)
Pages (from-to)52-55
Number of pages4
JournalThe Journal of infectious diseases
Volume215
Issue number1
DOIs
StatePublished - Jan 1 2017

Keywords

  • West Nile virus
  • flavivirus
  • vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers'. Together they form a unique fingerprint.

Cite this